Thyroid Eye Disease: Management Across the Spectrum of Severity and Chronicity (CE Monograph)

Activity Description and Purpose

This educational activity provides clinicians who currently treat patients with thyroid eye disease (TED) or have an interest in managing patients with TED with expert advice on diagnosis, current treatment approaches, and comanagement across the multidisciplinary team. A focused discussion on comanagement among eye care professionals and an endocrinologist provides the learner with practical strategies to optimize patient care. The desired results of this activity are to increase appropriate treatment of chronic TED in practice and to foster competent interdisciplinary collaboration to ensure the best possible outcomes for patients with chronic TED.

Target Audience

This educational activity is intended for optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Identify patients with thyroid eye disease who would be optimal candidates for treatment with biologic therapies
  • Apply evidence to manage thyroid eye disease in patients with chronic disease
Course summary
Available credit: 
  • 1.50 COPE
Course opens: 
Course expires: 


Wendy W. Lee, MD, MS (Chair)
Professor of Clinical Ophthalmology and Dermatology
Oculofacial Plastic & Reconstructive Surgery, Orbit, and Oncology
Bascom Palmer Eye Institute
University of Miami Miller School of Medicine
Miami, Florida

Roger A. Dailey, MD
Professor Ophthalmology
Lester T. Jones Chair of Oculoplastic Surgery
Casey Eye Institute
Oregon Health & Science University
Portland, Oregon

Andrew R. Harrison, MD
Department of Ophthalmology and Visual Neurosciences
Department of Otolaryngology, Head and Neck Surgery
Director, Ophthalmic Plastic and Reconstructive Surgery Service
Co-Director, Center for Thyroid Eye Disease
University of Minnesota
Minneapolis, Minnesota

Sonalika Khachikian, MD
Monument Health Rapid City Clinic
Rapid City, South Dakota

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.


Roger A. Dailey, MD, is a consultant for Amgen Inc and Viridian Therapeutics, Inc.

Andrew R. Harrison, MD, is a consultant for Amgen Inc and RVL Pharmaceuticals, Inc; and is on the speakers bureau for Amgen Inc and RVL Pharmaceuticals, Inc.

Sonalika Khachikian, MD, is a consultant for Amgen Inc; is on the speakers bureau for Amgen Inc; and is on the advisory board of Novo Nordisk A/S*.

Wendy W. Lee, MD, MS, is a consultant for Allergan, Amgen Inc, Novabay Pharmaceuticals, Inc, Revance Therapeutics, Inc, RVL Pharmaceuticals, Inc, and Tarsus Pharmaceuticals, Inc; and is a contracted researcher for Viridian Therapeutics, Inc.

Peer Reviewer

Hadi Kaakour, MD, was formerly an advisory board member of Alimera Sciences*.

Planners, Managers, and Writers

Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.

Other MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

Medical Writer: Tony Realini, MD, MPH,  is a consultant for New World Medical, Inc, Ocular Therapeutix, Inc, Oyster Point Pharma Inc, and Sight Sciences; and was previously a consultant for iStar Medical and Ivantis Inc within the past 2 years, but those relationships have ended.

* The financial relationship existed during the past 24 months but has now ended

Accreditation Statement

COPE approved for 1.5 CE credits for optometrists.
COPE Course ID: 89186-SD (Asynchronous)
COPE Course Category: Systemic Disease


This activity, COPE Activity Number 127576, is accredited by COPE for continuing education for optometrists.

Disclosure of Commercial Support

MedEdicus LLC has received commercial support from Amgen Inc for this activity in the form of an unrestricted educational grant.

The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Sponsored by

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Amgen Inc.

This CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 304.2b

Available Credit

  • 1.50 COPE
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CE information for this activity.